OTC · AOXG
Aoxing Pharmaceutical Company, Inc.
$0.00$0.00 (0.0%)
Aoxing Pharmaceutical Company, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.33% below the high.
Loading market information…
OTC · VIVXF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Avivagen Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Avivagen Inc.’s next earnings report is currently expected on Dec 30, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Avivagen Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Avivagen Inc. is a life sciences firm primarily engaged in creating and distributing specialized feed supplements for livestock. These products are designed to bolster animals' immune function and contribute to their enhanced growth and overall productivity. The company's diverse product portfolio includes OxC-beta Livestock, a key additive for animal feeds, alongside canine wellness offerings such as Vivamune and Dr. Tobias dog chews. Furthermore, Avivagen provides the Dr. Tobias Beta blend, formulated to support the human immune system. With a significant international footprint, Avivagen serves customers across the United States, Canada, the Philippines, Taiwan, Thailand, China, Mexico, Brazil, and Malaysia. The company was established in 2005 and is headquartered in Ottawa, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $68.74K-74.73% vs estimate |
| Q1 2022 | Mar 30, 2022 | -$0.03-50.0% vs estimate | $213.29K-32.21% vs estimate |
|---|
| Q4 2021 | Jan 19, 2022 | -$0.020.0% vs estimate | $297.88K-73.64% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
Aoxing Pharmaceutical Company, Inc.’s quoted price sits in the lower half of its reported 52-week range, 69.33% below the high.
$0.00$0.00 (0.0%)
HempAmericana, Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Real Brands, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
ViaDerma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.75% below the high.
$0.00$0.00 (0.0%)
Pazoo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Industry Source Consulting, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.0% below the high.
$0.00$0.00 (0.0%)
4Front Ventures Corp.’s quoted price sits in the lower half of its reported 52-week range, 96.67% below the high.
$0.00$0.00 (0.0%)
Global Hemp Group Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.98% below the high.
